Logo image of INBX

INHIBRX BIOSCIENCES INC (INBX) Stock Fundamental Analysis

USA - NASDAQ:INBX - US45720N1037 - Common Stock

27.6 USD
+0.95 (+3.56%)
Last: 9/19/2025, 8:19:26 PM
27.6 USD
0 (0%)
After Hours: 9/19/2025, 8:19:26 PM
Fundamental Rating

2

Taking everything into account, INBX scores 2 out of 10 in our fundamental rating. INBX was compared to 541 industry peers in the Biotechnology industry. While INBX seems to be doing ok healthwise, there are quite some concerns on its profitability. INBX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

INBX had negative earnings in the past year.
INBX had a negative operating cash flow in the past year.
INBX had negative earnings in 4 of the past 5 years.
INBX had a negative operating cash flow in each of the past 5 years.
INBX Yearly Net Income VS EBIT VS OCF VS FCFINBX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

1.2 Ratios

INBX has a Return On Assets of 795.58%. This is amongst the best in the industry. INBX outperforms 100.00% of its industry peers.
The Return On Equity of INBX (2461.49%) is better than 100.00% of its industry peers.
Industry RankSector Rank
ROA 795.58%
ROE 2461.49%
ROIC N/A
ROA(3y)268.02%
ROA(5y)139.35%
ROE(3y)153.62%
ROE(5y)40.8%
ROIC(3y)N/A
ROIC(5y)N/A
INBX Yearly ROA, ROE, ROICINBX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K

1.3 Margins

INBX has a Profit Margin of 843786.00%. This is amongst the best in the industry. INBX outperforms 100.00% of its industry peers.
The Operating Margin and Gross Margin are not available for INBX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) 843786%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INBX Yearly Profit, Operating, Gross MarginsINBX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 200K 400K 600K 800K

More info and screens

4

2. Health

2.1 Basic Checks

INBX does not have a ROIC to compare to the WACC, probably because it is not profitable.
INBX has less shares outstanding than it did 1 year ago.
The number of shares outstanding for INBX has been reduced compared to 5 years ago.
INBX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
INBX Yearly Shares OutstandingINBX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
INBX Yearly Total Debt VS Total AssetsINBX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

INBX has an Altman-Z score of -3.78. This is a bad value and indicates that INBX is not financially healthy and even has some risk of bankruptcy.
INBX has a Altman-Z score (-3.78) which is comparable to the rest of the industry.
A Debt/Equity ratio of 1.45 is on the high side and indicates that INBX has dependencies on debt financing.
INBX has a worse Debt to Equity ratio (1.45) than 79.11% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.45
Debt/FCF N/A
Altman-Z -3.78
ROIC/WACCN/A
WACC10.38%
INBX Yearly LT Debt VS Equity VS FCFINBX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

INBX has a Current Ratio of 4.98. This indicates that INBX is financially healthy and has no problem in meeting its short term obligations.
INBX has a Current ratio of 4.98. This is comparable to the rest of the industry: INBX outperforms 54.71% of its industry peers.
A Quick Ratio of 4.98 indicates that INBX has no problem at all paying its short term obligations.
The Quick ratio of INBX (4.98) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.98
Quick Ratio 4.98
INBX Yearly Current Assets VS Current LiabilitesINBX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for INBX have decreased strongly by -108.73% in the last year.
The Revenue for INBX has decreased by -88.89% in the past year. This is quite bad
Measured over the past years, INBX shows a very negative growth in Revenue. The Revenue has been decreasing by -56.75% on average per year.
EPS 1Y (TTM)-108.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-101.47%
Revenue 1Y (TTM)-88.89%
Revenue growth 3Y-69.76%
Revenue growth 5Y-56.75%
Sales Q2Q%1200%

3.2 Future

Based on estimates for the next years, INBX will show a very negative growth in Earnings Per Share. The EPS will decrease by -62.23% on average per year.
INBX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 449.31% yearly.
EPS Next Y-109.27%
EPS Next 2Y-44.44%
EPS Next 3Y-26.08%
EPS Next 5Y-62.23%
Revenue Next Year1200%
Revenue Next 2Y555.74%
Revenue Next 3Y1400.52%
Revenue Next 5Y449.32%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
INBX Yearly Revenue VS EstimatesINBX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M
INBX Yearly EPS VS EstimatesINBX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 20 40 60 80 100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for INBX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for INBX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INBX Price Earnings VS Forward Price EarningsINBX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INBX Per share dataINBX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10

4.3 Compensation for Growth

A cheap valuation may be justified as INBX's earnings are expected to decrease with -26.08% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-44.44%
EPS Next 3Y-26.08%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for INBX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INHIBRX BIOSCIENCES INC

NASDAQ:INBX (9/19/2025, 8:19:26 PM)

After market: 27.6 0 (0%)

27.6

+0.95 (+3.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-13 2025-08-13/amc
Earnings (Next)11-12 2025-11-12
Inst Owners60.59%
Inst Owner Change-7.63%
Ins Owners15.64%
Ins Owner Change0%
Market Cap399.92M
Analysts43.33
Price Target12.24 (-55.65%)
Short Float %8.28%
Short Ratio6.59
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)18.8%
Min EPS beat(2)3.29%
Max EPS beat(2)34.31%
EPS beat(4)3
Avg EPS beat(4)12.56%
Min EPS beat(4)-4.97%
Max EPS beat(4)34.31%
EPS beat(8)4
Avg EPS beat(8)432.66%
EPS beat(12)5
Avg EPS beat(12)284.73%
EPS beat(16)7
Avg EPS beat(16)211.02%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)35.07%
EPS NQ rev (3m)38.49%
EPS NY rev (1m)0%
EPS NY rev (3m)4.15%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1999.62
P/FCF N/A
P/OCF N/A
P/B 5.83
P/tB 5.83
EV/EBITDA N/A
EPS(TTM)-10.58
EYN/A
EPS(NY)-10.18
Fwd EYN/A
FCF(TTM)-9.67
FCFYN/A
OCF(TTM)-9.65
OCFYN/A
SpS0.01
BVpS4.73
TBVpS4.73
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 795.58%
ROE 2461.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 843786%
GM N/A
FCFM N/A
ROA(3y)268.02%
ROA(5y)139.35%
ROE(3y)153.62%
ROE(5y)40.8%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 1.45
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.2%
Cap/Sales 142%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.98
Quick Ratio 4.98
Altman-Z -3.78
F-Score3
WACC10.38%
ROIC/WACCN/A
Cap/Depr(3y)185.13%
Cap/Depr(5y)152.08%
Cap/Sales(3y)528.39%
Cap/Sales(5y)321.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-108.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-101.47%
EPS Next Y-109.27%
EPS Next 2Y-44.44%
EPS Next 3Y-26.08%
EPS Next 5Y-62.23%
Revenue 1Y (TTM)-88.89%
Revenue growth 3Y-69.76%
Revenue growth 5Y-56.75%
Sales Q2Q%1200%
Revenue Next Year1200%
Revenue Next 2Y555.74%
Revenue Next 3Y1400.52%
Revenue Next 5Y449.32%
EBIT growth 1Y-51.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year72.68%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y2.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.67%
OCF growth 3YN/A
OCF growth 5YN/A